| Ticker: | EVAX |
| Current Price: | $3.76 |
| % Daily Change: | 1.35% |
| Volume (1,000s): | 161.65 |
| Average Volume (1,000s): | 0.00 |
| Market Cap (M): | $23.75 |
| 1/2/2024 Price: | $4.55 |
| Change Since Inception: | -17.36% |
Dr. Neergaards Vej 5F
2970 Hørsholm
Denmark
Evaxion A/S (NASDAQ: EVAX) is a clinical-stage TechBio company that uses its AI-Immunology platform to design vaccines and immunotherapies for cancer and infectious diseases. Its lead candidate, EVX-01, is a personalized cancer vaccine in Phase 2 for advanced melanoma, and in October 2026 the company reported sustained clinical responses in all patients at three-year follow-up. The pipeline also includes EVX-04, an off-the-shelf vaccine for acute myeloid leukemia; EVX-05, an off-the-shelf vaccine program for glioblastoma; and infectious disease candidates including EVX-V1 for cytomegalovirus. In 2025, Evaxion licensed its AI-designed bacterial vaccine candidate EVX-B3 to MSD in a deal worth up to $592 million in milestone payments. Incorporated in 2008, Evaxion is headquartered in Hørsholm, Denmark.